Drug Trial Radar · NCT06457503
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 1, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Coherus Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Conditions
- Nasopharyngeal Cancer Recurrent
Interventions
ToripalimabDrug
Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
CisplatinDrug
Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
GemcitabineDrug
Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
CarboplatinDrug
In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by a Blinded Independent Central Review (BICR) Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Time frame: Up to 24 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
University of California, Irvine
Irvine, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer Center
Detroit, Michigan · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Withdrawn
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Princess Margaret Cancer Centre
Toronto, Canada, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.